Skip to main content

Table 2 Cox regression model adjusted for patient characteristics and therapeutic variables for hospital mortality

From: Beneficial effect modification on survival outcome of sepsis between ART-123 and polymyxin B‑immobilised haemoperfusion: a nationwide Japanese registry study

 Adjusted hazard ratio95% confidence intervalP value
ICU management policy
 ClosedReference
 Open1.1130.919–1.3480.275
 Other0.7440.584–0.9470.017
Admission route to the ICU
 Emergency departmentReference
 Another hospital0.8770.713–1.0780.211
 Ward0.9810.812–1.1870.847
Age (years)1.0131.006–1.020< 0.001
Male sex1.1250.947–1.3370.179
Body weight (kg)0.9910.984–0.9970.004
Pre-existing organ insufficiency or immunosuppression based on APACHE II score
 Liver1.2780.952–1.7160.102
 Respiratory1.4221.020–1.9830.038
 Cardiovascular1.3541.024–1.7900.034
 Renal1.4601.132–1.8850.004
 Immunocompromised1.0810.864–1.3520.497
Pre-existing haemostatic disorders
 Haematological malignancy1.1180.771–1.6190.556
 Chemotherapy0.9820.710–1.3600.915
 Warfarin intake0.7760.524–1.1500.206
 Other1.4640.939–2.2830.093
APACHE II score1.0351.023–1.047< 0.001
SOFA score1.0881.054–1.123< 0.001
SIRS score0.9530.869–1.0470.316
JAAM-DIC score1.0320.987–1.0790.161
Blood lactate (mmol/L)1.0831.066–1.100< 0.001
Blood culture
 Not takenReference
 Positive1.0830.690–1.7000.728
 Negative0.8850.573–1.3650.581
Microorganisms   
 UnknownReference
 Virus0.9450.400–2.2310.898
 Gram-negative rod0.7910.612–1.0230.074
 Gram-positive coccus0.9020.685–1.1880.463
 Fungus1.1580.644–2.0830.625
 Mixed infection1.0340.784–1.3640.810
 Others1.1260.642–1.9750.678
Primary source of infection
 UnknownReference
 Catheter-related bloodstream infection0.6310.317–1.2540.189
 Bone or soft tissue0.7650.525–1.1160.165
 Cardiovascular system0.5660.289–1.1090.097
 Central nervous system0.5790.328–1.0230.060
 Urinary tract0.5380.364–0.7940.002
 Lung or thoracic cavity1.0840.803–1.4640.598
 Abdomen0.7740.555–1.0790.131
 Other0.6250.290–1.3480.231
Specific treatments
 Surgical intervention0.7660.619–0.9480.014
 Mechanical ventilator (days)0.9770.967–0.987< 0.001
 Vasopressor1.2900.979–1.7010.070
 Immunoglobulins0.8590.719–1.0270.095
 Low-dose steroids1.4201.190–1.695< 0.001
Therapeutic interventions for DIC
 ART-1230.8340.695–0.9990.049
 Antithrombin0.8750.728–1.0530.158
 Protease inhibitors0.9160.727–1.1520.452
 Heparinoids1.0140.706–1.4570.940
Anti-thrombotic drugs for conditions other than DIC
 Heparin0.6900.537–0.8860.004
 Anti-platelet drugs0.6460.342–1.2210.179
 Nafamostat mesylate for blood purifications0.7020.553–0.8890.003
Blood purifications
 PMX-HP0.8970.720–1.1180.333
 RRT1.3831.090–1.7560.008
 RRT for non-renal indications1.3000.992–1.7040.057
 Plasma exchange1.4980.838–2.6770.172
  1. APACHE acute physiology and chronic health evaluation, DIC disseminated intravascular coagulation, ECMO extracorporeal membrane oxygenation, ICU intensive care unit, JAAM Japanese Association for Acute Medicine, PMX-HP polymyxin B‑immobilised haemoperfusion, RRT renal replacement therapy, SIRS systemic inflammatory response syndrome, SOFA sequential organ failure assessment